Loading...
Market
Story
FDA Approves Merck’s Keytruda with Chemotherapy for Advanced Mesothelioma
Sep 18, 2024, 10:48 AM
The FDA has approved Merck’s Keytruda (pembrolizumab) in combination with pemetrexed and platinum-based chemotherapy as a first-line treatment for adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM). This FDA approval marks a significant advancement for patients suffering from this rare and aggressive form of lung cancer.
View original story
Similar markets
0-2 trials • 25%
3-5 trials • 25%
6-8 trials • 25%
More than 8 trials • 25%
0-1 • 25%
2-3 • 25%
4-5 • 25%
More than 5 • 25%
0-5 trials • 25%
6-10 trials • 25%
11-15 trials • 25%
More than 15 trials • 25%
0-1 new treatments • 25%
2-3 new treatments • 25%
4-5 new treatments • 25%
More than 5 new treatments • 25%
0-5 trials • 25%
6-10 trials • 25%
11-15 trials • 25%
More than 15 trials • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
More than 5 trials • 25%
3 to 5 trials • 25%
1 to 2 trials • 25%
No new trials • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
0 • 25%
1 - 2 • 25%
3 - 4 • 25%
5 or more • 25%
None • 25%
1-2 companies • 25%
3-4 companies • 25%
More than 4 companies • 25%
0-5 trials • 25%
6-10 trials • 25%
11-15 trials • 25%
More than 15 trials • 25%
Less than 10,000 • 25%
10,000 to 50,000 • 25%
50,001 to 100,000 • 25%
More than 100,000 • 25%